Name: Tipifarnib (Zarnestra)
Price: 378.00 USD

- Overview
  - Please contact us at for specific academic pricing.
    
    Background
    
    Tipifarnib (also known as Zarnestra or R115777), an orally bioavailable quinolone analog of imidazole heterocyclics, is a potent and specific nonpeptidomimetic competitive inhibitor of farnesyltransferase (FTase), an enezyme mediating post-translational farnesylation of multiple protein substrates involved in tumor cell proliferation. It has demonstrated inhibition of growth and proliferation of a broad range of human tumor models (either wild-type or mutated RAS) via cytostatic rather than cytotoxic activity both in vitro and in vivo. It cell-type dependently induces apoptosis in some neoplastic cell lineages other than acute myeloid leukemia (AML), including multiple myeloma (MM) cell lines and MM cultures from patients.
- Properties
  - Alternative Name
    
    Zarnestra,R115777,R-115777,IND 58359; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one
    
    CAS Number
    
    192185-72-1
    
    Molecular Formula
    
    C27H22Cl2N4O
    
    Molecular Weight
    
    489.4
    
    Appearance
    
    A solid
    
    Purity
    
    99.18%
    
    Solubility
    
    insoluble in H2O; ≥8.16 mg/mL in DMSO; ≥9.16 mg/mL in EtOH with ultrasonic
    
    Storage
    
    Store at -20°C
    
    * For Research Use Only